Novo’s Refixia beats rival in head to head trial
admin 22nd May 2018 Uncategorised 0Novo Nordisk’s Refixia has come out on top in a head to head study assessing its effect in patients with the bleeding disorder haemophilia B against Swedish Orphan Biovitrum’s recombinant factor IX-Fc fusion protein (rFIXFc).
More: Novo’s Refixia beats rival in head to head trial
Source: News